KIDS Stock Analysis: Orthopediatrics | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 573m USD | 12M Return: 18.6% | US68752L1008 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.45M
Qual. Beats: 0
Rev. Trend: 98.2%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality
OrthoPediatrics Corp. (NASDAQ: KIDS) is a medical device company that designs, develops, and markets anatomically appropriate implants, instruments, and braces specifically for children with orthopedic conditions. Its product portfolio spans three main categories: pediatric trauma and deformity correction, scoliosis procedures, and sports medicine and other products, featuring a wide range of branded systems and platforms such as PediLoc, RESPONSE Spine, the Fassier-Duval Telescopic Intramedullary System, and the Boston Brace 3D. The company serves the pediatric orthopedic market, including pediatric orthopedic surgeons and caregivers, in both the United States and international markets. Founded in 2006 and headquartered in Warsaw, Indiana, OrthoPediatrics is a small-cap ($501M USD) health care supplies company that listed on NASDAQ in October 2017.
OrthoPediatrics operates in a specialized niche within the broader orthopedic device industry, which is largely dominated by large-cap manufacturers focused on adult populations. As a pure-play pediatric orthopedic company, its business model depends on surgeon relationships, recurring procedure-based revenue, and ongoing regulatory clearances and approvals from the U.S. Food and Drug Administration (FDA) for new and modified devices. Its broad product portfolio, which spans implants, instruments, and bracing, allows it to serve a wide range of procedures and patient ages within childrens orthopedics.
- Scoliosis and trauma segment revenue drives double-digit domestic growth
- Operating losses persist as salesforce expansion and acquisitions pressure margins
- International expansion lifts geographic revenue mix with European momentum
| Net Income: -39.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA 7.12 > 1.0 |
| NWC/Revenue: 79.00% < 20% (prev 99.23%; Δ -20.23% < -1%) |
| CFO/TA 0.01 > 3% & CFO 7.41m > Net Income -39.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.78 > 1.5 & < 3 |
| Outstanding Shares: last quarter (23.9m) vs 12m ago 2.24% < -2% |
| Gross Margin: 73.65% > 18% (prev 71.54%; Δ 2.11% > 0.5%) |
| Asset Turnover: 49.80% > 50% (prev 43.83%; Δ 5.97% > 0%) |
| Interest Coverage Ratio: -2.72 > 6 (EBIT TTM -22.8m / Interest Expense TTM 8.38m) |
| A: 0.39 (Total Current Assets 252.5m - Total Current Liabilities 52.9m) / Total Assets 511.4m |
| B: -0.57 (Retained Earnings -293.1m / Total Assets 511.4m) |
| C: -0.04 (EBIT TTM -22.8m / Avg Total Assets 507.5m) |
| D: 2.05 (Book Value of Equity 343.6m / Total Liabilities 167.8m) |
| Altman-Z'' = 2.54 = A |
| DSRI: 0.99 (Receivables 61.0m/53.8m, Revenue 252.7m/220.7m) |
| GMI: 0.97 (GM 71.54% / 73.65%) |
| AQI: 1.07 (AQ_t 0.41 / AQ_t-1 0.38) |
| SGI: 1.14 (Revenue 252.7m / 220.7m) |
| TATA: -0.09 (NI -39.7m - CFO 7.41m) / TA 511.4m) |
| Beneish M = -2.92 (Cap -4..+1) = A |
As of August 08, 2026, the stock is trading at USD 22.77 with a total of 195,066 shares traded. Over the past week, the price has changed by +12.78%, over one month by +14.88%, over three months by +29.60% and over the past year by +18.59%.
Current recommended Stop Loss: 19.80 (which is 13% or 2.7 ATR below the current price).
Orthopediatrics has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy KIDS.
- StrongBuy: 3
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 25.3 | 11.2% |
P/S = 2.2674
P/B = 1.5326
Revenue TTM = 252.7m USD
EBIT TTM = -22.8m USD
EBITDA TTM = -1.53m USD
Long Term Debt = 99.8m USD (from longTermDebt, last fiscal year)
Short Term Debt = 172k USD (from shortTermDebt, last quarter)
Debt = 100.3m USD (corrected: LT Debt 99.8m + ST Debt 172k) + Leases 320k
Net Debt = 54.4m USD (calculated: Debt 100.3m - CCE 45.9m)
Enterprise Value = 627.5m USD (573.0m + Debt 100.3m - CCE 45.9m)
Interest Coverage Ratio = -2.72 (Ebit TTM -22.8m / Interest Expense TTM 8.38m)
EV/FCF = -341.9x (Enterprise Value 627.5m / FCF TTM -1.83m)
FCF Yield = -0.29% (FCF TTM -1.83m / Enterprise Value 627.5m)
FCF Margin = -0.73% (FCF TTM -1.83m / Revenue TTM 252.7m)
Net Margin = -15.72% (Net Income TTM -39.7m / Revenue TTM 252.7m)
Gross Margin = 73.65% ((Revenue TTM 252.7m - Cost of Revenue TTM 66.6m) / Revenue TTM)
Gross Margin QoQ = 74.27% (prev 73.09%)
Tobins Q-Ratio = 1.23 (Enterprise Value 627.5m / Total Assets 511.4m)
Interest Expense / Debt = 8.36% (Interest Expense 8.38m / Debt 100.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -18.0m (EBIT -22.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.78 (Total Current Assets 252.5m / Total Current Liabilities 52.9m)
Debt / Equity = 0.29 (Debt 100.3m / totalStockholderEquity, last quarter 343.6m)
Debt / EBITDA = -35.65 (negative EBITDA) (Net Debt 54.4m / EBITDA -1.53m)
Debt / FCF = -29.66 (negative FCF - burning cash) (Net Debt 54.4m / FCF TTM -1.83m)
Total Stockholder Equity = 344.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.83% (Net Income -39.7m / Total Assets 511.4m)
RoE = -11.53% (Net Income TTM -39.7m / Total Stockholder Equity 344.6m)
RoCE = -5.13% (EBIT -22.8m / Capital Employed (Equity 344.6m + L.T.Debt 99.8m))
RoIC = -4.03% (negative operating profit) (NOPAT -18.0m / Invested Capital 446.1m)
WACC = 9.28% (E(573.0m)/V(673.3m) * Re(9.75%) + D(100.3m)/V(673.3m) * Rd(8.36%) * (1-Tc(0.21)))
Discount Rate = 9.75% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.86 | Cagr: 2.01%
[DCF] Fair Price = unknown (Cash Flow -1.83m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.78 | # QB: 0
Revenue Correlation: 98.16 | Revenue CAGR: 23.71% | SUE: 2.78 | # QB: 1
EPS current Quarter (2026-09-30): EPS=-0.18 | Chg30d=-7.06% | Revisions=-17% | Analysts=5
EPS current Year (2026-12-31): EPS=-1.08 | Chg30d=-2.88% | Revisions=+17% | GrowthEPS=-8.2% | GrowthRev=+12.4%
EPS next Year (2027-12-31): EPS=-0.74 | Chg30d=-9.12% | Revisions=+17% | GrowthEPS=+31.4% | GrowthRev=+11.8%
[Analyst] Revisions Ratio: +8% (up=5, down=4)